How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

46,663 results for

Cancer Pain Medications

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

, Los Angeles Los Angeles, CA Nancy Lane, M.D. Director and Distinguished Professor Center for Musculoskeletal Health and Department of Internal Medicine University of California at Davis, School of Medicine Sacramento, California Jasvinder Singh, M.D., M.P.H. Division of Rheumatology University of Alabama Birmingham, AL vii Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Structured Abstract Objective. To summarize the effects of long-term (...) Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Comparative Effectiveness Review Number 218 RComparative Effectiveness Review Number 218 Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600

2019 Effective Health Care Program (AHRQ)

2. Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas ? Assessment according to §137h Social Code Book V

for unresectable endocrine tumours. Overall, on the basis of the assessment documents submitted, a benefit or potential of a required treatment alternative can neither be inferred for the neoadjuvant nor for the disease- modifying or palliative use of USgHIFU for malignant neoplasms of the pancreas. For this reason, no key points for a testing study are specified for the method. The full report (German version) is published under https://www.iqwig.de/en/projects- results/projects/non-drug-interventions/h16-02c (...) the German original text is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. H16-02C Ultrasound-guided high- intensity focused ultrasound therapy for malignant neoplasms of the pancreas 1 Executive summary of assessment H16-02C according to §137h SGB V Version 1.0 USgHIFU for pancreatic tumours 30 January 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

3. Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas ? Addendum to commission H16-02C

Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas ? Addendum to commission H16-02C Addendum Auftrag: Version: Stand: 1.0 12.09.2017 IQWiG-Berichte – Nr. 538 Sonografiegesteuerte hochfokussierte Ultraschalltherapie bei bösartigen Neubildungen des Pankreas Addendum zum Auftrag H16-02C H17-03 Addendum H17-03 Version 1.0 USgHIFU bei Pankreastumoren 12.09.2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) - i - Impressum (...) Orgera 2011 [29] 1-armige Verlaufsbeobachtung 3 III: 3; k. A. zur vorherigen Therapie 3 (100) Chemo- und Radiotherapie 3 (100) Italien 1 3 3 inoperable, metastasierte neuro- endokrine Pankreastumore k. A. 3 (100) 2 (endokrine Tumore) Sofuni 2014 [30] 1-armige Verlaufsbeobachtung 30 III: 16, IV: 14; OP: 3, Chemotherapie: 28, Radiotherapie: 4, interventionelle Radiologie: 5 26 (87) f 24 Chemotherapie 2 Operation 1 (3) Japan 1 (Fortsetzung) Addendum H17-03 Version 1.0 USgHIFU bei Pankreastumoren

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

4. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients

Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients LABORATORY MEDICINE PRACTICE GUIDELINES EDITED BY LORALIE J. LANGMAN AND PAUL J. JANNETTO Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Co-Sponsored byLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Loralie J. Langman Committee Chair Department of Laboratory Medicine and Pathology Mayo Clinic (...) References 101 Table of ContentsLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients 5 Executive Summary Introduction The American Association for Clinical Chemistry (AACC) Acad- emy, formerly the National Academy of Clinical Biochemistry (NACB), has developed a laboratory medicine practice guidelines (LMPG) for using laboratory tests to monitor drug therapy in pain management patients. The scope and purpose of this guideline

2018 American Academy of Pain Medicine

5. Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience Full Text available with Trip Pro

Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience The use of large-field external beam reirradiation (re-RT) after pelvic radiation therapy (RT) for genitourinary (GU) cancers has not been reported. We report the results of such treatment in patients with either symptomatic GU second (...) malignant neoplasms or locally recurrent pelvic tumors after initial RT for whom surgery or further systemic therapy was not an option.The records of 28 consecutive patients with advanced, bulky GU malignancies treated with high-dose, large-field re-RT with palliative intent between 2008 and 2014 were retrospectively reviewed. Descriptive outcome analyses focused on toxicities and symptom control, and responses were evaluated by 2 independent observers.Twenty-seven male patients (96%) were included

2017 Advances in radiation oncology

6. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) have been prescribed the longest. Targeted synthetic disease- modifying antirheumatic drugs (tsDMARDs) were approved more recently. Additionally, many trials or observational studies in this review evaluated mainly FDA-approved biologic drugs (both tumor necrosis factor [TNF] and non-TNF drugs). The FDA has approved numerous biosimilars. We evaluated the benefits and harms of multiple drug monotherapies, combination therapies (...) csDMARD Studies 22 KQ 1: Comparative Benefits of Drug Therapies for Patients With Early RA in Relation to Disease Activity, Progression of Radiographic Joint Damage, or Remission 27 Key Points 27 Detailed Synthesis 28 KQ 2: Comparative Benefits of Drug Therapies for Patients With Early RA in Relation to Patient-Reported Symptoms, Functional Capacity, or Quality of Life 59 Key Points 60 Detailed Synthesis 74 KQ 3: Comparative Harms of Drug Therapies for Patients With Early RA in Relation to Harms

2018 Effective Health Care Program (AHRQ)

7. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

Diabetes Canada, have acknowledged that there may be a role for adjunctive therapy in some T1D patients. 10,23,40 In the US, pramlintide acetate injection (Symlin) is the only noninsulin drug approved for adjunctive treatment of T1D. 13,29 Metformin, a T2D medication, is mentioned by Diabetes Canada and the American Diabetes Association for off-label use to reduce insulin requirements and total cholesterol/low-density lipoprotein ratios, 10,17,23 with the caveat that it does not improve hemoglobin A1C (...) Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? | CADTH.ca CADTH Document Viewer Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Table of Contents Search this document Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? January 2018 Summary There are two major

2018 CADTH - Issues in Emerging Health Technologies

8. Clinical analysis of high risk factors for pelvic malignant tumors after hysterectomy for benign diseases. Full Text available with Trip Pro

Clinical analysis of high risk factors for pelvic malignant tumors after hysterectomy for benign diseases. To analyze the clinicopathological characteristics of pelvic masses after hysterectomy for benign diseases, and to analyze the related factors of benign and malignant pelvic masses.This study retrospectively analyzed the patients undergone reoperation for pelvic mass subsequently to hysterectomy for benign disease from January 2012 to December 2016 in Peking Union Medical College (...) of abdominal distension and abdominal pain, while most of those with benign masses were diagnosed during physical examination. Patients with malignant pelvic masses had medical imagines of mixed masses, extraovarian derivation, as well as elevated carbohydrate antigen-125 (CA 125). Multivariate analysis showed that ages of having hysterectomy, physical examination results, abnormal defecation, cystic and solid masses, and elevated CA 125 level were independent risk factors for benign and malignant pelvic

2019 Medicine

9. Efficacy of computed tomography-guided implantation of 125I seeds in the treatment of refractory malignant tumors accompanied with cancer pain and its influence on tumor markers in the serum. (Abstract)

Efficacy of computed tomography-guided implantation of 125I seeds in the treatment of refractory malignant tumors accompanied with cancer pain and its influence on tumor markers in the serum. This study intended to explore the efficacy of computed tomography (CT)-guided implantation of iodine-125 (125I) seeds in the treatment of refractory malignant tumors with cancer pain and its influence on tumor markers in the serum.76 patients with refractory malignant tumors accompanied by cancer pain (...) evident than that in the control group (p<0.05).Our results showed that CT-guided implantation of 125I seeds is effective for the treatment of patients with refractory malignant tumors accompanied by cancer pain. It can reduce the levels of tumor markers, improve the survival rate and prolong the survival time of the patients.

2018 European review for medical and pharmacological sciences Controlled trial quality: uncertain

10. Management of Female Malignant Ovarian Germ Cell Tumours

treatment Women who have residual masses at completion of chemotherapy should be offered resection even if the tumour markers are normal. 41 This is to exclude residual disease or any residual mature teratoma which can progress as mature teratoma growing syndrome in up to 30% of cases, and more rarely, over time, undergo malignant transformation into an incurable tumour type, such as squamous carcinoma. Early recognition of this syndrome is essential as it offers hope for curative resection and avoids (...) for female malignant germ cell tumors. Obstet Gynecol 2006;107: 1075–85. 6. Arora RS, Alston RD, Eden TO, Geraci M, Birch JM. Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003. Cancer 2012;118:4290–7. 7. Talerman A. Germ cell tumours of the ovary. In: Kurman RJ, editor. Blaustein’s Pathology of the Female Genital Tract. New York: Springer Verlag; 1994. p. 849. 8. Tewari K, Cappuccini F , Disaia PJ, Berman ML, Manetta A, Kohler MF . Malignant

2016 Royal College of Obstetricians and Gynaecologists

11. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. Full Text available with Trip Pro

Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. A recent randomized-withdrawal, active- and placebo-controlled, double-blind phase 3 study showed that tapentadol prolonged release (PR) was effective and well tolerated for managing moderate to severe, chronic malignant tumour-related pain in patients who were opioid naive or dissatisfied with current treatment (Pain Physician, 2014, 17, 329-343). This post hoc (...) /tapentadol PR subgroup (69.8% [90/129]) vs. the overall tapentadol PR group (63.9% [214/335]). Tolerability profiles were comparable for both groups.Results of this subgroup analysis indicate that patients with cancer pain could safely switch from prior treatment with the weak centrally acting analgesic tramadol directly to the strong centrally acting analgesic tapentadol PR, for an improved analgesic therapy for severe pain. WHAT DOES THIS STUDY ADD?: Results of this post hoc analysis show that patients

2018 European journal of pain (London, England) Controlled trial quality: uncertain

12. Gabapentin as an adjuvant therapy for prevention of acute phantom-limb pain in pediatric patients undergoing amputation for malignant bone tumors: a prospective double-blind randomized controlled trial. Full Text available with Trip Pro

Gabapentin as an adjuvant therapy for prevention of acute phantom-limb pain in pediatric patients undergoing amputation for malignant bone tumors: a prospective double-blind randomized controlled trial. Gabapentin is reported to have an analgesic effect of reducing phantom-limb pain (PLP) in adult patients. There is no study on preoperative use of gabapentin in pediatric population in terms of PLP prevention.To determine whether gabapentin could be used as an adjuvant agent of opioid-based pain (...) control to lower the rate of PLP in pediatric patients undergoing amputation for malignant bone tumors in observation period of 60 days postoperatively.Pediatric patients who were diagnosed with osteosarcoma or Ewing's sarcoma around the knee and underwent amputation from May 2013 to March 2016 were registered to this prospective double-blind randomized controlled trial. Four days before amputation, the patients were randomized to a study group receiving oral gabapentin, and a control group receiving

2017 Journal of pain and symptom management Controlled trial quality: predicted high

13. Biotechnologically produced drugs as second-line therapy for rheumatoid arthritis

as second-line therapy in patients with RA. The assessment was based on patient- relevant outcomes. In this context, “treatment extension” is understood as continued therapy initiated as a supplementation to existing therapy. For the present commission, for biotechnologically produced drugs (biologic disease modifying anti-rheumatic drugs, bDMARDs), second-line therapy, i.e. therapy after failure of previous treatment, was to be distinguished from first-line therapy, i.e. therapy in treatment- naive (...) patients. In the present benefit assessment, the definition of second-line therapy therefore covered the use of biotechnologically produced drugs in persons who had been pretreated with at least one disease-modifying antirheumatic drug, also including biotechnologically produced ones. Methods The assessment was conducted on the basis of randomized controlled trials (RCTs) on the research question stated above. For this purpose a systematic literature search was conducted in the following databases

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

14. Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Patient Version

Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Patient Version Ovarian Low Malignant Potential Tumors Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information (...) directly into the , an , or a body such as the abdomen, the drugs mainly affect cancer cells in those areas ( ). The way the chemotherapy is given depends on the type and of the cancer being treated. New types of treatment are being tested in clinical trials. Information about clinical trials is available from the . Treatment for ovarian low malignant potential tumors may cause side effects. For information about caused by treatment for cancer, see our page. Patients may want to think about taking part

2018 PDQ - NCI's Comprehensive Cancer Database

15. Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non?Opioid Drug Use: A Systematic Review Full Text available with Trip Pro

Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non?Opioid Drug Use: A Systematic Review Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non‐Opioid Drug Use: A Systematic Review - Lindstrøm - 2013 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Brief Strategic Family Therapy (BSFT (...) this review and refer to an addiction stage of non‐medical drug usage; this definition implies that the term ‘use’ refers to the consumption of drugs beyond experimentation and into addiction. of the kind that persists beyond the experimentation phase is a severe problem worldwide (United Nations Office of Drugs and Crime (UNODC), 2010), and the use of non‐opioid drugs such as cannabis, amphetamines and cocaine is strongly associated with a broad range of health and social problems, including delinquency

2013 Campbell Collaboration

16. Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. Full Text available with Trip Pro

to recurrence of malignant skull base tumors. Twenty-two patients received single-fraction GKRS to a median dose of 17 Gy (range 15-20 Gy) prescribed to the 50% isodose line (range 43%-55%). Four patients received fractionated Gamma Knife Extend therapy to a median dose of 24 Gy in 3 fractions (range 21-27 Gy) prescribed to the 50% isodose line (range 45%-50%). Those with at least a 3-month follow-up were assessed for symptom palliation. Self-reported pain was evaluated by the numeric rating scale (NRS (...) Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. OBJECTIVEThe objective of this study was to assess outcomes after Gamma Knife radiosurgery (GKRS) re-irradiation for palliation of patients with trigeminal pain secondary to recurrent malignant skull base tumors.METHODSFrom 2009 to 2016, 26 patients who had previously undergone radiation treatment to the head and neck received GKRS for palliation of trigeminal neuropathic pain secondary

2018 Journal of Neurosurgery

17. Clinically significant drug-drug interactions involving medications used for symptom control in patients with advanced malignant disease. A systematic review. (Abstract)

Clinically significant drug-drug interactions involving medications used for symptom control in patients with advanced malignant disease. A systematic review. Most patients with advanced malignant disease need to take several drugs to control symptoms. This treatment raises risks of serious adverse effects and drug-drug interactions (DDIs).To identify studies reporting clinically significant DDIs involving medications used for symptom control, other than opioids used for pain management (...) publications were case reports, letters to the Editor and one retrospective study. Drugs most often involved were antiepileptics, antidepressants, corticosteroids and non-opioid analgesics. Clinical manifestations of identified DDIs included sedation, respiratory depression, serotonin syndrome, neuroleptic malignant syndrome, delirium, seizures, ataxia, liver and kidney failure, bleeding, cardiac arrhythmias, rhabdomyolysis and others. The most common mechanisms eliciting DDIs were alteration of CYP450

2019 Journal of pain and symptom management

18. Gastrointestinal malignant neoplasms disguised as pneumatosis cystoids intestinalis: A case report and literature review. Full Text available with Trip Pro

, gastrointestinal malignant neoplasms might rarely present as PCI and neoplastic etiologies should also be considered once PCI is detected. Because most patients with malignant PCIs might inevitably experience severe complications, abdominal surgery should be considered and applied timely after unsuccessful resolution by conservative medical therapies and symptomatic treatments.Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved. (...) Gastrointestinal malignant neoplasms disguised as pneumatosis cystoids intestinalis: A case report and literature review. Pneumatosis cystoids intestinalis (PCI) is a rare disease in which gas develops in the mucosa or submucosa of the digestive tract. The etiology and pathogenesis of this disease, at present, remain unclear, and gastrointestinal malignant neoplasms may be a potentially important cause. Herein, we report a case of mantle cell lymphoma presenting as PCI as well as present

2017 Medicine

19. Application of embolization microspheres in interventional therapy of malignant non-hypervascular tumor of liver Full Text available with Trip Pro

Application of embolization microspheres in interventional therapy of malignant non-hypervascular tumor of liver To investigate the efficacy and safety of transarterial embolization (TAE) using embolization microspheres in the treatment of non-hypervascular malignant liver tumors.Patients with malignant non-hypervascular liver tumors, who were treated with TAE using embolization microspheres, were selected and analyzed retrospectively. The technical success rate, tumor response (...) , and complications were assessed.Six patients were included in the study: 1 patient each with hepatocellular-cholangiocarcinoma, intrahepatic cholangiocarcinoma, hepatic metastasis after resection of common bile duct carcinoma, liver metastasis from colon cancer, liver metastasis from esophageal cancer, and liver metastasis from pancreatic cancer. The technical success rate was 100%. At 1 and 3 months after TAE, tumor local reactions were seen in 6/6 and 2/6 patients, respectively, and the tumor necrosis rates

2017 Oncotarget

20. Niraparib (Zejula) - Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

. Discussion on clinical safety 106 2.6.2. Conclusions on the clinical safety 110 2.7. Risk Management Plan 110 2.8. New Active Substance 113 2.9. Product information 113 2.9.1. User consultation 113 2.9.2. Additional monitoring 113 Assessment report EMA/648982/2017 Page 3/122 3. Benefit-Risk Balance 114 3.1. Therapeutic Context 114 3.1.1. Disease or condition 114 3.1.2. Available therapies and unmet medical need 114 3.1.3. Main clinical studies 115 3.2. Favourable effects 115 3.3. Uncertainties (...) first detected in advanced stages when prognosis is poor. Assessment report EMA/648982/2017 Page 10/122 The 5-year overall survival rate of ovarian cancer patients is 46% across all stages and only 29% in patients diagnosed with distant metastatic disease. Most patients will die within 3 to 4 years of diagnosis [Coleman et al 2013]. 2.1.5. Management The majority of patients with ovarian cancer receive surgery to remove or debulk the tumour. The primary treatment of advanced-stage ovarian cancer

2017 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>